144 related articles for article (PubMed ID: 36171093)
21. Substitutions of different regions of the third cytoplasmic loop of the thyrotropin (TSH) receptor have selective effects on constitutive, TSH-, and TSH receptor autoantibody-stimulated phosphoinositide and 3',5'-cyclic adenosine monophosphate signal generation.
Kosugi S; Okajima F; Ban T; Hidaka A; Shenker A; Kohn LD
Mol Endocrinol; 1993 Aug; 7(8):1009-20. PubMed ID: 7901757
[TBL] [Abstract][Full Text] [Related]
22. Exosomes Expressing Thyrotropin Receptor Attenuate Autoantibody-Mediated Stimulation of Cyclic Adenosine Monophosphate Production.
Edo N; Kawakami K; Fujita Y; Morita K; Uno K; Tsukamoto K; Onose H; Ishikawa T; Ito M
Thyroid; 2019 Jul; 29(7):1012-1017. PubMed ID: 31062662
[No Abstract] [Full Text] [Related]
23. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
24. Biased signaling by thyroid-stimulating hormone receptor-specific antibodies determines thyrocyte survival in autoimmunity.
Morshed SA; Ma R; Latif R; Davies TF
Sci Signal; 2018 Jan; 11(514):. PubMed ID: 29363585
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of functional and immunological responses to thyroid-stimulating antibodies from patients with Graves' disease by blockade of the thyrotropin receptor.
Hoermann R; Schumm-Draeger PM; Mann K
Thyroid; 1993; 3(4):273-8. PubMed ID: 7906974
[TBL] [Abstract][Full Text] [Related]
26. Hormone- and antibody-mediated activation of the thyrotropin receptor.
Duan J; Xu P; Luan X; Ji Y; He X; Song N; Yuan Q; Jin Y; Cheng X; Jiang H; Zheng J; Zhang S; Jiang Y; Xu HE
Nature; 2022 Sep; 609(7928):854-859. PubMed ID: 35940204
[TBL] [Abstract][Full Text] [Related]
27. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease.
Mizutori Y; Chen CR; Latrofa F; McLachlan SM; Rapoport B
J Clin Endocrinol Metab; 2009 Mar; 94(3):927-35. PubMed ID: 19066298
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of Action of TSHR Autoantibodies.
Furmaniak J; Sanders J; Núñez Miguel R; Rees Smith B
Horm Metab Res; 2015 Sep; 47(10):735-52. PubMed ID: 26361260
[TBL] [Abstract][Full Text] [Related]
29. TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.
Krieger CC; Neumann S; Gershengorn MC
Pharmacol Ther; 2020 May; 209():107502. PubMed ID: 32061922
[TBL] [Abstract][Full Text] [Related]
30. TSH receptor-adenovirus-induced Graves' hyperthyroidism is attenuated in both interferon-gamma and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm.
Nagayama Y; Saitoh O; McLachlan SM; Rapoport B; Kano H; Kumazawa Y
Clin Exp Immunol; 2004 Dec; 138(3):417-22. PubMed ID: 15544617
[TBL] [Abstract][Full Text] [Related]
31. Thyrotropin receptor antibodies: new insights into their actions and clinical relevance.
Ando T; Latif R; Davies TF
Best Pract Res Clin Endocrinol Metab; 2005 Mar; 19(1):33-52. PubMed ID: 15826921
[TBL] [Abstract][Full Text] [Related]
32. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
[TBL] [Abstract][Full Text] [Related]
34. A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor.
Neumann S; Eliseeva E; McCoy JG; Napolitano G; Giuliani C; Monaco F; Huang W; Gershengorn MC
J Clin Endocrinol Metab; 2011 Feb; 96(2):548-54. PubMed ID: 21123444
[TBL] [Abstract][Full Text] [Related]
35. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
[TBL] [Abstract][Full Text] [Related]
36. TSH receptor antibodies do not alter the function of gonadotropin receptors stably expressed in eukaryotic cells.
Tonacchera M; Ferrarini E; Dimida A; Agretti P; De Marco G; De Servi M; Chiovato L; Cetani F; Vitti P; Pinchera A
Eur J Endocrinol; 2004 Mar; 150(3):381-7. PubMed ID: 15012625
[TBL] [Abstract][Full Text] [Related]
37. Exceptional hyperthyroidism and a role for both major histocompatibility class I and class II genes in a murine model of Graves' disease.
McLachlan SM; Aliesky HA; Chen CR; Williams RW; Rapoport B
PLoS One; 2011; 6(6):e21378. PubMed ID: 21738647
[TBL] [Abstract][Full Text] [Related]
38. Utility of systematic TSHR gene testing in adults with hyperthyroidism lacking overt autoimmunity and diffuse uptake on thyroid scintigraphy.
Patel KA; Knight B; Aziz A; Babiker T; Tamar A; Findlay J; Cox S; Dimitropoulos I; Tysoe C; Panicker V; Vaidya B
Clin Endocrinol (Oxf); 2019 Feb; 90(2):328-333. PubMed ID: 30372544
[TBL] [Abstract][Full Text] [Related]
39. Gangliosides, the thyrotropin receptor, and autoimmune thyroid disease.
Lacetti P; Tombaccini D; Aloj S; Grollman EF; Kohn LD
Adv Exp Med Biol; 1984; 174():355-67. PubMed ID: 6331133
[TBL] [Abstract][Full Text] [Related]
40. Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity.
Costagliola S; Bonomi M; Morgenthaler NG; Van Durme J; Panneels V; Refetoff S; Vassart G
Mol Endocrinol; 2004 Dec; 18(12):3020-34. PubMed ID: 15319453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
